source
- Roche halts obesity antibody emugrobart after negative phase 2 interim readoutRoche has stopped development of its obesity antibody emugrobart after an interim analysis of a phase 2 trial indicated a low chance of meeting the study endpoints. The antibody, designed to block…
- Mirum's Phase 3 Trial Shows Brelovitug Achieves Primary Endpoint in Hepatitis D StudyMirum Pharmaceuticals reported that its phase 3 Azure-1 trial in chronic hepatitis delta met its primary efficacy goal, marking a significant step toward market entry in a field dominated by Gilead…